[Thienylic acid, a new drug with saluretic and uricosuric activity. Preliminary data].
The effects of ticrynafen (250-500 mg) on salt-water and uric acid metabolism have been studied in 18 patients with no haemodinamic abnormalities or salt-water repletion (cardiac failure, oedema). The main results are: -- an effective natriuresis is observed in the first days and is attenuated thereafter. In subjects with a reduced GFR, a negative salt balance is obtained altough the volume of diuresis is not significantly increased. -- The potassium loss is variable according to dosage (maximum at 500 mg), renal function (low when reduced). -- The increase of urinary uric acid excretion and the lowering of blood uric acid concentration are rapid and prolonged. In conclusion, we confirm the effective natriuretic and uricosuric properties of ticrynafen.
D000328:Adult; D000368:Aged; D004232:Diuretics / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006016:Glycolates / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010642:Phenoxyacetates / Q000494:pharmacology / Q000627:therapeutic use*; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use*; D014527:Uric Acid / Q000378:metabolism; D014528:Uricosuric Agents / Q000627:therapeutic use*; D014882:Water-Electrolyte Balance / Q000187:drug effects*
D004232:Diuretics; D006016:Glycolates; D010642:Phenoxyacetates; D013876:Thiophenes; D014528:Uricosuric Agents; D014527:Uric Acid
Acido tienilico, nuovo farmaco ad azione saluretica ed uricosurica. Rilievi preliminari.